NEWS AND EVENTS
NEWS AND EVENTS
Positive data from Sanifit’s Phase 2b CaLIPSO trial of SNF472 published in Circulation
SNF472 significantly reduced progression of cardiovascular calcification in patients with end stage kidney disease (ESKD) receiving hemodialysis SNF472 treated patients had coronary artery calcium (CAC) volume score progression of 11% from baseline versus 20% in patients receiving placebo (P=0.016) SNF472 was well tolerated Results are remarkable as they have been achieved in patients who […]
Sanifit announces that the Phase 2b CaLIPSO trial of SNF472 met its primary endpoint in slowing the progression of cardiovascular calcification in patients on hemodialysis
Top line data to be presented at 2019 Scientific Sessions of American Heart Association Webcast to be held on Monday 18 November at 11.00 ET Palma, Spain and San Diego, USA, 30 October 2019 – Sanifit, a clinical-stage biopharmaceutical company focused on treatments for progressive vascular calcification disorders, today announced that the international Phase 2b […]
Sanifit named as one of 2019’s “Fierce 15” biotechnology companies by FierceBiotech
Palma, Spain and San Diego, USA, 23 September 2019 – Sanifit, a clinical-stage biopharmaceutical company focused on treatments for progressive vascular calcification disorders, today announced that it has been named by FierceBiotech as one of 2019’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry. In […]
Sanifit announces €72.2M ($80.9M) financing in Spain’s largest private biotech fundraise
– Proceeds to enable progression of orphan designated lead candidate SNF472 into pivotal phase 3 trial for treatment of calciphylaxis – Round led by Spanish investor Caixa Capital Risc – Deal supported by new investors Columbus Venture Partners and Alta Life Sciences in addition to international consortium of existing shareholders Palma, Spain and San […]
Data from SNF472 Phase 1b Clinical Trial published in British Journal of Clinical Pharmacology
Data show SNF472 inhibits induction of HAP crystallization Results provide support for further development of SNF472 as a novel treatment for CUA Palma, Spain and San Diego, USA, 4 March, 2019 – Sanifit, a clinical-stage biopharmaceutical company focused on the treatment of conditions related to progressive vascular calcification, today announces the publication in the […]
Latest News
UPCOMING EVENTS
11th-14th January – JPMorgan, San Francisco, USA
4th – 6th April – BIO Europe Spring, Stockholm, Sweden
27th April – 1st May – NKF Clinical Meeting, Boston, USA
21st – 24th May – ERA – EDTA, VIenna, Austria
6th – 9th June – BIO, San Francisco, USA
7th – 9th November – BIO Europe, Cologne, Germany
15th – 20th November – ASN Kidney Week, Chicago, USA